Study of Apatinib in Metastatic Esophageal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02683655|
Recruitment Status : Unknown
Verified February 2016 by Huai'an First People's Hospital.
Recruitment status was: Recruiting
First Posted : February 17, 2016
Last Update Posted : February 17, 2016
|Condition or disease||Intervention/treatment||Phase|
|Esophageal Cancer||Drug: Apatinib||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of Apatinib in Metastatic Esophageal Cancer：A Open Label, Randomized Clinical Trial|
|Study Start Date :||August 2015|
|Estimated Primary Completion Date :||October 2016|
Experimental: Apatinib 500mg qd p.o.
Apatinib Mesylate Tablets 500 mg qd p.o. after the failure of chemotherapy or radiotherapy
Apatinib 500mg qd p.o.
Experimental: Apatinib 750mg qd p.o.
Apatinib Mesylate Tablets 750 mg qd p.o. after the failure of chemotherapy or radiotherapy
Apatinib 750mg qd p.o.
- Progression free survival [ Time Frame: An expected average of 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02683655
|Contact: Chen xiaofei, MD||+86-13915107001|
|Huaian First People's Hospital||Recruiting|
|Huaian, Jiangsu, China|
|Contact: Chen xiaofei, MD +86-13915107001|